Neovasc Reducer™ Featured in Live Case Session at TCT 2014 Scientific Symposium

Tiara™ Transcatheter Mitral Valve program featured in multiple scientific presentations 

NASDAQ: NVCN
TSX: NVC

WASHINGTON, DC, Sept. 15, 2014 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) announced today that its Reducer™ technology was featured in a "live case" broadcast on Sunday, September 14, 2014 at the 26th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.  A Clinical update on the company's Tiara™ transcatheter mitral valve (TMVI) program was also presented. TCT is the world's largest educational meeting specializing in interventional cardiovascular medicine and is being held September 13^th -17^th, 2014 in Washington DC.

In a live case broadcast in the main arena of the conference, Dr. Marc Jolicoeur and Dr. Serge Doucet of Montreal Heart Institute (Montreal, Canada) successfully implanted a Neovasc Reducer in the coronary sinus of a 79-year-old patient suffering from severe refractory angina. The implantation was completed successfully,  without any procedural complications. The Neovasc Reducer gained CE mark in 2011. It is indicated for use in the treatment of patients diagnosed with refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. 

"This live case broadcast of a Reducer implantation in a patient with complex cardiovascular disease and no other therapeutic options demonstrates the ease and utility of the procedure as a means to provide relief of debilitating angina symptoms in this patient population," commented Neovasc CEO, Alexei Marko, "Early compassionate use experience with our Tiara TMVI device, developed for the treatment of mitral regurgitation, is also encouraging and we look forward to the commencement of our TIARA-I Feasibility trial which is expected to begin in later 2014".

Neovasc's Tiara transcatheter mitral valve was also featured in multiple scientific sessions at TCT and Dr. Anson Cheung, Professor of Surgery and Director of Cardiac Transplant at St. Paul's Hospital, Vancouver Canada presented an update on the Tiara transcatheter mitral valve clinical program. Dr. Cheung indicated that the Tiara valve has now been successfully implanted in three patients under compassionate use.

About Neovasc Inc. 

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Tiara™ technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer™ for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; the merits and the Company's defence of the lawsuits filed by CardiAQ, listing of the Company's securities on the TSX, our anticipated use of proceeds from any financings, a history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.

SOURCE: Neovasc Inc.

Investor Relations: Neovasc Inc., Chris Clark, 604 248-4138,, [email protected]